Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alpharma’s Embeda Has “Incremental Benefit” In Reducing Opioid Abuse, FDA Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee expresses concern over variability in benefit seen among patients; many still experience euphoria sought by opioid abusers.

You may also be interested in...



Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning

Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins

Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning

Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins

Pain Therapeutics’ Remoxy Is More Abuse-Resistant Than Other Oxycodone Formulations, FDA Panel Suggests

Approval may depend on FDA’s confidence that the firm’s proposed REMS can adequately monitor for abuse – a subject of apparent debate within FDA.

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel